willow health tirzepatide Eli Lilly’s Lawsuit Loss! Eli Lilly sues companies selling

95% CI 0.600.88), DPP-4i (aHR, 0.72

These newer agents may further assist in the effective pharmacological management of T2D through the provision of patient-centered care that acknowledges multimorbidity and is respectful of and responsive to individual patient preferences and barriers

*Source Euromonitor International Limited

Denied insurance coverage for Wegovy, Zepbound, and other GLP-1s

As one obesity medicine specialist put it, the amount of muscle mass that can be lost in a single year on a GLP-1 medication may be equivalent to eight to ten years of age-related muscle decline

Keep one in your bag, one in the car, one in your suitcase